Yuhan (000100) Fundamentals 2026 — P/E 27.8x, Revenue Analysis | SniperIQ
Yuhan (000100) is a KR-listed Healthcare company in Drug Manufacturers - Specialty & Generic with a market capitalization of ₩5.17T, trading at ₩70200.00 on the KSC. This SniperIQ fundamentals page covers Yuhan's valuation (P/E 27.8x, P/B 2.5x), profitability (net margin 9.6%), revenue (₩2.19T in FY2025), balance-sheet quality, and AI signal context — from live market data, research only.
Full research coverage
- 8-Quarter Revenue & Margin Trend
- Debt Maturity & Coverage
- Peer Valuation Comparison
- Free Cash Flow & Owner Earnings
- AI Signal + Institutional Flow
- DCF Valuation Model
Frequently Asked Questions
What is Yuhan's market cap?
Yuhan (000100) has a market capitalization of approximately ₩5.17T, trading at ₩70200.00 on the KSC. Market cap moves with the live share price.
What is Yuhan's P/E ratio?
Yuhan's trailing twelve-month P/E ratio is 27.8x, with a price-to-book (P/B) of 2.5x. Valuation multiples are best compared with Healthcare sector peers rather than read in isolation.
How profitable is Yuhan?
Yuhan runs a net profit margin of 9.6%, a gross margin of 33.6%, and an operating margin of 4.8%. Margins and ROE indicate how efficiently the business converts sales into profit and shareholder returns.
How much revenue does Yuhan generate?
Yuhan reported revenue of ₩2.19T for fiscal year 2025, with net income of ₩194.1B and earnings per share (EPS) of 2599. SniperIQ tracks the full 8-quarter revenue and margin trend on the research dashboard.
Does Yuhan pay a dividend?
Yuhan offers a trailing dividend yield of about 0.9%. Dividend sustainability depends on payout ratio, free cash flow, and earnings stability — all tracked in SniperIQ's fundamentals view.
Is Yuhan financially healthy?
Yuhan carries a debt-to-equity ratio of 0.16x and a current ratio of 2.03x, with a market beta of 0.41. Lower leverage and a current ratio above 1.0 generally signal a stronger balance sheet.
Is Yuhan a good stock to buy in 2026?
SniperIQ provides research-only market intelligence, not personalised financial advice or a buy/sell call. For Yuhan (000100) the key facts are: market cap ₩5.17T, P/E 27.8x, revenue ₩2.19T, 52-week range 65000-129200. Weigh valuation, profitability, growth, and balance-sheet strength against Healthcare peers and form your own view.
Track Yuhan's full fundamentals live
Get Yuhan's 8-quarter revenue and margin trend, peer comparison, DCF model, and AI signal on the SniperIQ research dashboard.